<prompt> Answer this question truthfullyWhat medical treatment is recommended for individuals coinfected with HIV and tuberculosis?  <response>: <reason> The principles for treatment of active tuberculosis TB disease in HIV-infected patients are the same as those for HIV-uninfected patients AI. All HIV-infected patients with diagnosed active TB should be started on TB treatment immediately AI. All HIV-infected patients with diagnosed active TB should be treated with antiretroviral therapy ART AI. In patients with CD4 counts 50 cellsmm3, ART should be initiated within 2 weeks of starting TB treatment AI. In patients with CD4 counts 50 cellsmm3 who present with clinical disease of major severity as indicated by clinical evaluation including low Karnofsky score, low body mass index BMI, low hemoglobin, low albumin, organ system dysfunction, or extent of disease, ART should be initiated within 2 to 4 weeks of starting TB treatment. The strength of this recommendation varies on the basis of CD4 cell count: CD4 count 50 to 200 cellsmm3 BI CD4 count 200 cellsmm3 BIII In patients with CD4 counts 50 cellsmm3 who do not have severe clinical disease, ART can be delayed beyond 2 to 4 weeks of starting TB therapy but should be started within 8 to 12 weeks of TB therapy initiation. The strength of this recommendation also varies on the basis of CD4 cell count: CD4 count 50 to 500 cellsmm3 AI CD4 count 500 cellsmm3 BIII In all HIV-infected pregnant women with active TB, ART should be started as early as feasible, both for maternal health and for prevention of mother-to-child transmission PMTCT of HIV AIII. In HIV-infected patients with documented multidrug-resistant MDR and extensively drug-resistant XDR TB, ART should be initiated within 2 to 4 weeks of confirmation of TB drug resistance and initiation of second-line TB therapy BIII. Despite pharmacokinetic drug interactions, a rifamycin rifampin or rifabutin should be included in TB regimens for patients receiving ART, with dosage adjustment if necessary AII. Rifabutin is the preferred rifamycin to use in HIV-infected patients with active TB disease on a protease inhibitor PI-based regimen because the risk of substantial drug interactions with PIs is lower with rifabutin than with rifampin AII. Coadministration of rifampin and PIs with or without ritonavir RTV boosting is not recommended AII. Rifapentine RPT is NOT recommended in HIV-infected patients receiving ART for treatment of latent TB infection LTBI or active TB, unless in the context of a clinical trial AIII. Immune reconstitution inflammatory syndrome IRIS may occur after initiation of ART. Both ART and TB treatment should be continued while managing IRIS AIII. Treatment support, which can include directly observed therapy DOT of TB treatment, is strongly recommended for HIV-infected patients with active TB disease AII. 